赛诺医疗科学技术股份有限公司2025 年半年度报告 公司代码：688108 公司简称：赛诺医疗 赛诺医疗科学技术股份有限公司 2025 年半年度报告 1 / 179 赛诺医疗科学技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真 实性、准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述了公司在经营过程中可能面临的各种风险及应对措 施，具体内容详见本报告第三节"管理层讨论与分析之风险因素"部分的阐述，敬请 投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人孙箭华、主管会计工作负责人 沈立华 及会计机构负责人（会计主 管人员）沈立华 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 九、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 十、 是否 ...

每经AI快讯，8月21日，赛诺医疗(688108.SH)公告称，公司上半年营业收入为2.40亿元，同比增长 12.53%；净利润为1384.16万元，同比增长296.54%。 ...

赛诺医疗公告，2025年上半年营业收入2.4亿元，同比增长12.53%。净利润1384.16万元，同比增长 296.54%。 ...

New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has a tender offer period from August 12, 2025, to September 10, 2025[1] - Changcheng Military Industry (601606) announced a significant event on August 14, 2025[1] Market Alerts - Dongxin Co., Ltd. (688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (600200) has an announcement dated August 21, 2025, regarding market conditions[1] - Yunnan Zhiye (002428) and other companies have recent announcements on August 21, 2025, indicating market activity[1] Financial Performance - ST Jiangsu (600021) reported significant fluctuations on August 20, 2025, with a notable announcement[1] - ST Huanrong (600421) has an announcement dated August 20, 2025, reflecting market conditions[1] - ST Jinhong (000669) reported on August 20, 2025, indicating financial performance concerns[1]

Market Overview - The A-share market experienced a sudden decline in the afternoon, with the Shanghai Composite Index dropping over 0.2% before recovering slightly, while the Shenzhen Component and ChiNext indices fell [2] - The trading volume in the Shanghai and Shenzhen markets exceeded 2 trillion yuan for the first time this year, marking the seventh consecutive trading day of such volume [2] Sector Performance - Securities stocks collectively faced a pullback, with notable declines including Changcheng Securities down over 6% and Hato Securities down over 5% [2][3] - Several high-priced stocks hit the daily limit down, including Lianhuan Pharmaceutical and Zhongdian Xindong, with others like Shunlian Bio and Sainuo Medical dropping over 8% [4] Banking Sector - In contrast, bank stocks showed strength in the afternoon, with Agricultural Bank of China and Postal Savings Bank reaching new historical highs during the session [2] Hong Kong Market - The Hang Seng Index fell over 0.5%, and the Hang Seng Tech Index dropped more than 1% [6] - AAC Technologies Holdings (02018.HK) saw a rapid decline of over 14% following the release of its interim results, despite reporting a revenue of 13.32 billion yuan, a year-on-year increase of 18.4% [6][8] Company Performance - AAC Technologies reported a gross margin of 20.7%, down 0.8 percentage points year-on-year, attributed to changes in product mix, while net profit attributable to shareholders increased by 63.1% to 876 million yuan due to improved profitability in optical business and rapid growth in precision structural components [8] - CICC noted that the overall valuation level of A-shares remains reasonable, but the rapid increase in trading volume may lead to short-term volatility [8]

Group 1 - A-share market experienced a decline in high-performing stocks in the afternoon session, with several companies hitting the daily limit down [1] - Notable companies that faced significant drops include Lianhuan Pharmaceutical, Zhongdian Xindong, Feilong Co., Jintian Co., which all hit the limit down, while Shenlian Biological, Sainuo Medical, Jimin Health, Wolong Electric Drive, Chuanrun Co., Hanzhong Precision, and Guangsheng Tang all fell over 8% [1]

Group 1 - A-share market experienced a decline in high-performing stocks in the afternoon session, with companies such as Lianhuan Pharmaceutical, Zhongdian Xilong, Feilong Co., and Jintian Co. hitting the daily limit down [1] - Other companies like Shenlian Bio, Sainuo Medical, Jimin Health, Wolong Electric Drive, Chuanrun Co., Hanzhong Precision, and Guangsheng Tang saw declines exceeding 8% [1] Group 2 - MACD golden cross signal has formed, indicating a positive trend for certain stocks [2]

Group 1 - The core point of the news is that Sino Medical has seen significant financing activity, with a total financing buy amount of 3.78 billion yuan on August 20, ranking 51st in the market [1] - Over the last three trading days, Sino Medical received financing buy amounts of 4.03 billion yuan, 4.70 billion yuan, and 3.78 billion yuan respectively [1] - On the same day, the financing repayment amount was 4.05 billion yuan, resulting in a net sell of 26.51 million yuan [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on that day [2]

Group 1 - The stock exchange has implemented monitoring measures for stocks that exhibit significant abnormal fluctuations in trading, particularly focusing on large buy or sell orders within a one-minute timeframe during continuous bidding phases [1] Group 2 - A list of stocks under abnormal fluctuation monitoring has been provided, including *ST Suwu, Sainuo Medical, and Dongxin Technology, with specific monitoring start and end dates [2]

Group 1 - The medical device sector has gained significant attention, with 125 out of 131 companies in the A-share market experiencing stock price increases in the past month, and Sino Medical Science Technology Co., Ltd. achieving a remarkable stock price increase of 207.59% [1] - Institutional investors are actively researching the medical device industry, indicating a reassessment of growth potential in this sector [1] - The Chinese government has introduced supportive policies to accelerate the high-quality development of the medical device industry, aiming to transition from a major pharmaceutical country to a strong one [1] Group 2 - In July, the National Medical Products Administration released measures to support innovation in high-end medical devices, including medical robots and AI medical devices, highlighting the government's focus on high-end innovation [2] - The high-end medical device market in China is projected to grow rapidly, with an estimated market size of 2.8 trillion yuan by 2030, driven by technological advancements and domestic replacements [2] - The push for high-end innovation is expected to break the "low-end lock-in" in the medical device industry, enhancing the overall value and international competitiveness of the sector [2] Group 3 - Companies like Maide Medical Industrial Equipment Co., Ltd. are expanding their overseas channels through exhibitions and customer visits, with overseas orders expected to exceed 60 million yuan by the end of 2024 [3] - Anjies Medical Technology Co., Ltd. is deepening its global layout through localized operations and overseas production bases, successfully selling products to over 60 countries [3] - The global demand for medical devices is increasing, particularly in emerging markets, providing significant opportunities for Chinese medical device companies to expand internationally [3]